Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering

Alzai Health Corp. has announced its intention to pursue an initial public offering (IPO) with a target deal size of up to $4 million. The Toronto-based health technology company filed a final long-form prospectus on April 21, 2026, with regulatory authorities in British Columbia, Alberta, and Ontario. The offering will consist of a minimum of 8 million units priced at $0.40 each, with the potential to increase to 10 million units. Each unit comprises one common share and one-half of a common share purchase warrant, with the warrants exercisable at $0.60 per share for a period of 24 months following the closing date, which is anticipated to occur around May 21, 2026.

Alzai Health Corp. specializes in developing innovative health technology solutions, particularly focusing on Alzheimer's disease and related dementia. The company's flagship product is an artificial intelligence-driven, non-invasive risk screening solution that leverages existing patient data from routine clinical records. This approach aims to facilitate earlier diagnosis of cognitive decline, addressing a significant gap in the current healthcare landscape, where approximately 80% of Alzheimer's patients receive a diagnosis only after the disease has progressed to more advanced stages. By enabling timely interventions, Alzai's technology seeks to improve patient outcomes and support population-level disease management.

The strategic rationale behind this IPO is to raise capital for research and development, sales and marketing, and general working capital. The funds raised will be crucial for Alzai as it seeks to enhance its product offerings and expand its market presence. The health technology sector is witnessing rapid growth, driven by increasing demand for innovative solutions that improve patient care and outcomes. As healthcare systems globally strive to manage the rising incidence of chronic diseases, companies like Alzai are well-positioned to capitalize on this trend.

Haywood Securities Inc. is acting as the exclusive agent for the offering, operating on a best-efforts basis. The agent will receive a commission of 7% of the proceeds, along with agent's warrants and a corporate finance fee. The anticipated trading of Alzai's common shares on the TSX Venture Exchange under the symbol "ALZI" marks a significant milestone for the company and reflects growing investor interest in health technology innovations.

The broader market implications of Alzai's IPO highlight a growing recognition of the importance of early diagnosis and intervention in managing chronic diseases. As the health technology sector continues to evolve, investors are increasingly focused on companies that offer scalable solutions to pressing healthcare challenges. Alzai's successful public offering could pave the way for further investment in the sector, encouraging innovation and competition among emerging health technology firms.